| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CRF-binding protein (CRF-BP). CRF(6-33)(human) is a peptide inhibitor of CRF-BP that competitively binds to CRF-BP but does not bind to postsynaptic CRF receptors. By displacing CRF from CRF-BP, it increases the availability of free CRF to act on CRF receptors. This modulates the HPA axis and stress responses.
|
|---|---|
| ln Vitro |
CRF(6-33)(human) is a CRF-BP ligand inhibitor that competitively binds to CRF-BP but not to postsynaptic CRF receptors. By displacing CRF from CRF-BP, it increases free CRF levels. This mechanism underlies its in vivo effects on body weight and motor activity.
|
| ln Vivo |
In vivo, CRF(6-33)(human) suppresses body weight gain and increases motor activity in obese rats. By displacing CRF from CRF-BP, it increases free CRF levels, which can modulate feeding behavior, energy expenditure, and locomotor activity. Its anti-obesity effects make it a valuable tool for studying the role of CRF in metabolic regulation.
|
| Enzyme Assay |
In vitro binding assays are used to characterize CRF(6-33)(human) as a CRF-BP inhibitor. Radioligand binding assays are performed using CRF-BP protein, and the compound's ability to displace labeled CRF from CRF-BP is measured to confirm its competitive binding.
|
| Cell Assay |
Cellular assays for CRF(6-33)(human) involve treating cells or tissues expressing CRF-BP with the compound and measuring the displacement of CRF. Functional readouts include the measurement of free CRF levels or downstream signaling through CRF receptors. These assays confirm the compound's mechanism of action as a CRF-BP inhibitor.
|
| Animal Protocol |
In vivo efficacy of CRF(6-33)(human) is evaluated in animal models of obesity and metabolic disorders. The compound is administered via injection, and its effects on body weight, food intake, motor activity, and metabolic parameters are assessed. Its ability to suppress body weight gain in obese rats demonstrates its potential for studying CRF-BP in metabolic regulation.
|
| ADME/Pharmacokinetics |
CRF(6-33)(human) is a peptide derived from the human CRF sequence. As a peptide, its pharmacokinetic properties would be characteristic of this class, with a short half-life. It is typically administered via injection for in vivo studies. The compound should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for CRF(6-33)(human). As a CRF-BP inhibitor, its safety profile would be an important consideration. Potential toxicities could be related to its effects on the HPA axis and stress responses. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications.
|
| References |
|
| Additional Infomation |
CRF(6-33)(human) (CAS#: 120066-38-8) is a CRF-binding protein (CRF-BP) ligand inhibitor. It competitively binds to CRF-BP but not to postsynaptic CRF receptors. It suppresses body weight gain and increases motor activity in obese rats. It is a research tool for studying stress-related signaling, HPA axis regulation, and metabolic disorders.
|
| Molecular Formula |
C141H231N41O43S
|
|---|---|
| Molecular Weight |
3220.66
|
| Exact Mass |
3218.69
|
| CAS # |
120066-38-8
|
| Related CAS # |
CRF(6-33)(human) TFA
|
| PubChem CID |
91976998
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.968
|
| Hydrogen Bond Donor Count |
47
|
| Hydrogen Bond Acceptor Count |
49
|
| Rotatable Bond Count |
112
|
| Heavy Atom Count |
226
|
| Complexity |
7420
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XHHPINGDTRCKNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C141H231N41O43S/c1-23-72(16)109(145)136(221)179-100(61-183)135(220)174-93(52-68(8)9)129(214)176-99(58-108(195)196)133(218)173-95(54-70(12)13)134(219)182-111(77(21)185)138(223)178-96(55-78-29-25-24-26-30-78)130(215)175-98(57-80-60-151-64-155-80)131(216)172-92(51-67(6)7)128(213)171-91(50-66(4)5)126(211)163-82(32-28-47-153-141(148)149)119(204)166-88(38-44-107(193)194)124(209)181-110(71(14)15)137(222)177-94(53-69(10)11)127(212)167-87(37-43-106(191)192)122(207)168-89(45-48-226-22)118(203)158-73(17)112(197)160-81(31-27-46-152-140(146)147)116(201)156-74(18)113(198)162-86(36-42-105(189)190)121(206)165-85(35-41-104(144)188)123(208)170-90(49-65(2)3)125(210)159-75(19)114(199)161-84(34-40-103(143)187)120(205)164-83(33-39-102(142)186)117(202)157-76(20)115(200)169-97(56-79-59-150-63-154-79)132(217)180-101(62-184)139(224)225/h24-26,29-30,59-60,63-77,81-101,109-111,183-185H,23,27-28,31-58,61-62,145H2,1-22H3,(H2,142,186)(H2,143,187)(H2,144,188)(H,150,154)(H,151,155)(H,156,201)(H,157,202)(H,158,203)(H,159,210)(H,160,197)(H,161,199)(H,162,198)(H,163,211)(H,164,205)(H,165,206)(H,166,204)(H,167,212)(H,168,207)(H,169,200)(H,170,208)(H,171,213)(H,172,216)(H,173,218)(H,174,220)(H,175,215)(H,176,214)(H,177,222)(H,178,223)(H,179,221)(H,180,217)(H,181,209)(H,182,219)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H,224,225)(H4,146,147,152)(H4,148,149,153)
|
| Chemical Name |
5-[[5-amino-1-[[1-[[1-[[5-amino-1-[[5-amino-1-[[1-[[1-[(1-carboxy-2-hydroxyethyl)amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-[2-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-methylpentanoyl)amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoylamino]-5-carbamimidamidopentanoyl]amino]propanoylamino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3105 mL | 1.5525 mL | 3.1050 mL | |
| 5 mM | 0.0621 mL | 0.3105 mL | 0.6210 mL | |
| 10 mM | 0.0310 mL | 0.1552 mL | 0.3105 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
